TAS-102 for the treatment of metastatic colorectal cancer

References

• Magalhaes B, Peleteiro B, Lunet N. Dietary patterns and colorectal cancer: systematic review and meta-analysis. Eur J Cancer Prev. 2012;21:15–23.
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386.
   PubMed Web of Science ®Google Scholar
• Torre LA, Bray F, Rl S, et al. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
   PubMed Web of Science ®Google Scholar
• Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15:1065–1075.
   PubMed Web of Science ®Google Scholar
• Lenz HJ, Niedzwiecki D, Innocenti F, et al. CALGB/SWOG 80405: PHASE III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded ras analyses untreated metastatic adenocarcinoma of the colon or rectum (MCRC). Ann Oncol. 2014;25(Supplement 5):v1–v41.
   Google Scholar
• Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371:1609–1618.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381:303–312.
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919.
   PubMed Web of Science ®Google Scholar
• Reyes P, Heidelberger C. Fluorinated pyrimidines. XXVI. Mammalian thymidylate synthetase: its mechanism of action and inhibition by fluorinated nucleotides. Mol Pharmacol. 1965;1:14–30.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Emura T, Fukushima M. Mode of action of trifluorothymidine (TFT) against DNA replication and repair enzymes. Int J Oncol. 2011;39:263–270.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Suzuki N, Emura T, et al. Structure and activity of specific inhibitors of thymidine phosphorylase to potentiate the function of antitumor 2ʹ-deoxyribonucleosides. Biochem Pharmacol. 2000;59:1227–1236.
   PubMed Web of Science ®Google Scholar
• Matsushita S, Nitanda T, Furukawa T, et al. The effect of a thymidine phosphorylase inhibitor on angiogenesis and apoptosis in tumors. Cancer Res. 1999;59:1911–1916.
   PubMed Web of Science ®Google Scholar
• Temmink OH, Emura T, de Bruin M, et al. Therapeutic potential of the dual-targeted TAS-102 formulation in the treatment of gastrointestinal malignancies. Cancer Sci. 2007;98:779–789.
   PubMed Web of Science ®Google Scholar
• Peters GJ, Backus HH, Freemantle S, et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta. 2002;1587:194–205.
   PubMed Web of Science ®Google Scholar
• Eckstein JW, Foster PG, Finer-Moore J, et al. Mechanism-based inhibition of thymidylate synthase by 5-(trifluoromethyl)-2ʹ-deoxyuridine 5ʹ-monophosphate. Biochemistry. 1994;33:15086–15094.
   PubMed Web of Science ®Google Scholar
• Santi DV, Sakai TT. Thymidylate synthetase. Model studies of inhibition by 5-trifluoromethyl-2ʹ-deoxyuridylic acid. Biochemistry. 1971;10:3598–3607.
   PubMed Web of Science ®Google Scholar
• Tanaka N, Sakamoto K, Okabe H, et al. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep. 2014;32:2319–2326.
   PubMed Web of Science ®Google Scholar
• Oguchi K, Sakamoto K, Kazuno H, et al. TAS-102 treatment results in high trifluridine incorporation into DNA with pyrimidine metabolic pathway markedly up-regulated in cancer. Eur J Cancer. 2014;50(suppl 6):15. Abstract 27.
   Google Scholar
• Matsuoka K, Iimori M, Niimi S, et al. Trifluridine induces p53-dependent sustained G2 phase arrest with its massive misincorporation into DNA and few DNA strand breaks. Mol Cancer Ther. 2015;14:1004–1013.
   PubMed Web of Science ®Google Scholar
• Lenz H-J, Stintzing S, Loupakis F. TAS-102, a novel antitumor agent: a review of the mechanism of action. Cancer Treat Rev. 2015. DOI:10.1016/j.ctrv.2015.06.001.
   PubMedGoogle Scholar
• Saif MW, Syrigos K, Mehra R, et al. Dihydropyrimidine dehydrogenase deficiency (Dpd) in Gi malignancies: experience of 4-years. Pak J Med Sci. 2007;23:832–839.
   PubMed Web of Science ®Google Scholar
• Emura T, Murakami Y, Nakagawa F, et al. A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells. Int J Mol Med. 2004;13:545–549.
   PubMed Web of Science ®Google Scholar
• Emura T, Suzuki N, Yamaguchi M, et al. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA. Int J Oncol. 2004;25:571–578.
   PubMed Web of Science ®Google Scholar
• Inaba M, Mitsuhashi J, Sawada H, et al. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. Jpn J Cancer Res. 1996;87:212–220.
   PubMedGoogle Scholar
• Moghaddam A, Bicknell R. Expression of platelet-derived endothelial cell growth factor in Escherichia coli and confirmation of its thymidine phosphorylase activity. Biochemistry. 1992;31:12141–12146.
   PubMed Web of Science ®Google Scholar
• Hong DS, Abbruzzese JL, Bogaard K, et al. Phase I study to determine the safety and pharmacokinetics of oral administration of TAS-102 in patients with solid tumors. Cancer. 2006;107:1383–1390.
   PubMed Web of Science ®Google Scholar
• Doi T, Ohtsu A, Yoshino T, et al. Phase I study of TAS-102 treatment in Japanese patients with advanced solid tumours. Br J Cancer. 2012;107:429–434.
   PubMed Web of Science ®Google Scholar
• Green MC, Pusztai L, Rl T, et al. Phase I study to determine the safety of oral administration of TAS-102 on a twice daily (BID) schedule for five days a week (wk) followed by two days rest for two wks, every (Q) four wks in patients (pts) with metastatic breast cancer (MBC). Proc Am Soc Clin Oncol. 2006; 25. Abstract 10576.
   Google Scholar
• Overman MJ, Kopetz S, Varadhachary G, et al. Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008;26:794–799.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Varadhachary G, Kopetz S, et al. Phase 1 study of TAS-102 administered once daily on a 5-day-per-week schedule in patients with solid tumors. Invest New Drugs. 2008;26:445–454.
   PubMed Web of Science ®Google Scholar
• Pouremad R, Bahk KD, Yj S, et al. Quantitative 19F NMR study of trifluorothymidine metabolism in rat brain. NMR Biomed. 1999;12:373–380.
   PubMed Web of Science ®Google Scholar
• Dexter DL, Wolberg WH, Fj A, et al. The clinical pharmacology of 5-trifluoromethyl-2ʹ-deoxyuridine. Cancer Res. 1972;32:247–253.
   PubMed Web of Science ®Google Scholar
• Cleary JM, Mayer JR, Van Cutsem E, et al. Population pharmacokinetic (PK) analysis of TAS-102 in patients (pts) with metastatic colorectal cancer (mCRC): Results from 3 phase 1 trials and the phase 3 RECOURSE trial. J Clin Oncol. 2015;33:15 (suppl);abstr 2579.
   Google Scholar
• A phase I study of TAS-102 in patients with advanced solid tumors with renal impairment [Internet]. [cited 2015 Jul 28]. https://clinicaltrials.gov/ct2/show/NCT02301117?term=tas-102&rank=5
   Google Scholar
• Patel MR, Bendell JC, Mayer RJ, et al. A phase I dose-escalation study of TAS-102 in patients (pts) with refractory metastatic colorectal cancer (mCRC). J Clin Oncol. 2012;30:(suppl; abstr 3631).
   PubMed Web of Science ®Google Scholar
• Yoshino T, Mizunuma N, Yamazaki K, et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 2012;13:993–1001.
   PubMed Web of Science ®Google Scholar
• Komatsu Y, Yoshino T, Mizunuma N, et al. The relevance of thymidine kinase 1 (TK1) expression to treatment efficacy of TAS-102 and prognosis in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer. 2013;49:suppl 2.
   Google Scholar
• Li J, Qin S, Xu R, et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2015;16:619–629.
   PubMed Web of Science ®Google Scholar
• Expanded access study of TAS-102 in patients with metastatic colorectal cancer [Internet]. [cited 2015 Jun 18] https://clinicaltrials.gov/ct2/show/NCT02286492?term=TAS-102&rank=13
   Google Scholar
• Study of TAS-102 in patients with metastatic colorectal cancer in Asia (TERRA) [Internet]. [cited 2015 Jun 8]. https://clinicaltrials.gov/ct2/show/NCT01955837?term=TAS-102&rank=9
   Google Scholar